NDATOPICALOINTMENT
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADQUEY (difamilast) is a topical ointment that works as a phosphodiesterase-4 (PDE-4) inhibitor, approved in February 2026. It reduces cytokine and chemokine production by increasing intracellular cyclic AMP levels, though its exact therapeutic mechanism remains incompletely defined. The product is positioned as a dermatological agent for topical use.
Launch10.5 years to LOE
Early-stage launch phase with moderate competitive pressure (18/100) suggests building commercial infrastructure and market education efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
Started Oct 2022
153 enrolled
Atopic Dermatitis
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
Started Sep 2022
542 enrolled
Atopic Dermatitis
Career Relevance
ADQUEY represents a launch-stage opportunity with early career exposure to dermatology market dynamics and competitive positioning strategy. The compressed 5-year exclusivity window demands rapid execution, making this ideal for career growth in commercial launch and brand-building roles.
Brand Manager
Worked on ADQUEY at Acrotech Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.